We are live on ! Find out more
ORKA

Oruka Therapeutics
ORKA

15 hedge funds and large institutions have $27.9M invested in Oruka Therapeutics in 2015 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

15% more funds holding

Funds holding: 13 → 15 (+2)

6% less capital invested

Capital invested by funds: $29.7M → $27.9M (-$1.77M)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

Holders
15
Holders Change
+2
Holders Change %
+15.38%
% of All Funds
0.39%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
4
Increased
3
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$166K
2
Citadel Advisors
Citadel Advisors
Florida
+$92.8K
3
Deutsche Bank
Deutsche Bank
Germany
+$66.8K
4
VKH
Virtu KCG Holdings
New York
+$22.6K
5
BFA
BlackRock Fund Advisors
California
+$3.4K

Top Sellers

Rank Fund Capital Flow
1
VM
VHCP Management
New York
-$5.66M
2
RCM
RA Capital Management
Massachusetts
-$173K
3
TRCT
Tower Research Capital (TRC)
New York
-$43K
4
Bank of America
Bank of America
North Carolina
-$7.93K
5
UBS Group
UBS Group
Switzerland
-$5.66K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$6.79M – – –
Franklin Resources
2
Franklin Resources
California
$5.66M – – –
VMI
3
VHCP Management II
New York
$5.02M +$5.66M +4,995 New
TCM
4
Tekla Capital Management
Massachusetts
$3.77M – – –
RCM
5
RA Capital Management
Massachusetts
$3.62M -$173K -153 -4%
VM
6
VHCP Management
New York
$2.15M -$5.66M -4,995 -70%
Vanguard Group
7
Vanguard Group
Pennsylvania
$553K +$166K +147 +36%
Deutsche Bank
8
Deutsche Bank
Germany
$175K +$66.8K +59 +51%
Citadel Advisors
9
Citadel Advisors
Florida
$83K +$92.8K +82 New
VKH
10
Virtu KCG Holdings
New York
$68K +$22.6K +20 +43%
Bank of America
11
Bank of America
North Carolina
$3K -$7.93K -7 -70%
BFA
12
BlackRock Fund Advisors
California
$3K +$3.4K +3 New
TRCT
13
Tower Research Capital (TRC)
New York
$1K -$43K -38 -97%
Wells Fargo
14
Wells Fargo
California
$1K – – –
Citigroup
15
Citigroup
New York
$1K +$1.13K +1 New
UBS Group
16
UBS Group
Switzerland
– -$5.66K -5 Closed
Walleye Trading
17
Walleye Trading
New York
– -$3K -3 Closed

ORKA Hedge Fund Activity: Q4 2015 in Review

15 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q4 2015, worth a combined $27.9M — down 6% from $29.7M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new ORKA positions and 2 closed out — a net gain of 2 holders — while 3 added to existing stakes and 4 trimmed.

The largest buyer was Vanguard Group, adding an estimated $166K. The largest seller was VHCP Management, cutting an estimated $5.66M.

  • 15 institutional investors held Oruka Therapeutics (ORKA) as of Q4 2015, up from 13 in Q3 2015.
  • Funds reported $27.9M of Oruka Therapeutics stock for Q4 2015, down 6% quarter-over-quarter.
  • 4 funds opened new Oruka Therapeutics positions in Q4 2015 and 2 closed out, a net change of +2 holders.
  • The largest Oruka Therapeutics buyer in Q4 2015 was Vanguard Group, an estimated $166K added.
  • The largest Oruka Therapeutics seller in Q4 2015 was VHCP Management, an estimated $5.66M sold.

Based on aggregated 13F filings for Q4 2015.